GlaxoSmithKline Consumer Healthcare Pakistan (KASE:GSKCH) - Share price, News & Analysis

GSKCH fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

GSKCH Stock Overview

GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan.

Rewards

PE ratio (12.8x) is below the Personal Products industry average (20.9x)

Earnings grew by 69.1% over the past year

Risk Analysis

High level of non-cash earnings

GlaxoSmithKline Consumer Healthcare Pakistan Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GlaxoSmithKline Consumer Healthcare Pakistan
Historical stock prices
Current Share Price	PK₨234.00
52 Week High	PK₨303.96
52 Week Low	PK₨210.10
Beta	1.04
1 Month Change	-7.49%
3 Month Change	-10.77%
1 Year Change	3.38%
3 Year Change	23.97%
5 Year Change	-20.14%
Change since IPO	259.70%

Shareholder Returns

	GSKCH	PK Personal Products	PK Market
7D	-2.1%	-1.5%	-3.3%
1Y	3.4%	-21.0%	-9.9%

Return vs Industry: GSKCH exceeded the PK Personal Products industry which returned -21% over the past year.

Return vs Market: GSKCH exceeded the PK Market which returned -9.9% over the past year.

Price Volatility

Is GSKCH's price volatile compared to industry and market?
GSKCH volatility
GSKCH Average Weekly Movement	3.8%
Personal Products Industry Average Movement	6.0%
Market Average Movement	5.7%
10% most volatile stocks in PK Market	8.8%
10% least volatile stocks in PK Market	3.6%

Stable Share Price: GSKCH is less volatile than 75% of PK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: GSKCH's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	459	Farhan Haroon	https://www.pk-consumerhealthcare.gsk.com

GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan. The company offers products in the areas of pain relief under the Panadol and IODEX brands; oral health under the Sensodyne and Parodontax brand names; respiratory health under the Panadol CF, Sancos, T-Day, Tandegyl, and Actified brands; nutrition and gastrointestinal health under the CaC-1000 PLUS, ENO, and Horlicks brand names; and skin health under the Physiogel, Hydrozole, SunBlock 60, Lamisil, Acne Aid, Duofilm, Brevoxyl, and Oilatum brands. It also exports its products.

GlaxoSmithKline Consumer Healthcare Pakistan Fundamentals Summary

How do GlaxoSmithKline Consumer Healthcare Pakistan's earnings and revenue compare to its market cap?
GSKCH fundamental statistics
Market Cap	PK₨27.39b
Earnings (TTM)	PK₨2.13b
Revenue (TTM)	PK₨24.16b

12.8x

P/E Ratio

1.1x

P/S Ratio

Is GSKCH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GSKCH income statement (TTM)
Revenue	PK₨24.16b
Cost of Revenue	PK₨17.51b
Gross Profit	PK₨6.65b
Other Expenses	PK₨4.52b
Earnings	PK₨2.13b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	18.23
Gross Margin	27.53%
Net Profit Margin	8.83%
Debt/Equity Ratio	1.7%

How did GSKCH perform over the long term?

See historical performance and comparison

Valuation

Is GlaxoSmithKline Consumer Healthcare Pakistan undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

12.83x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: GSKCH (PKR234) is trading above our estimate of fair value (PKR9.37)

Significantly Below Fair Value: GSKCH is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: GSKCH is good value based on its PE Ratio (12.8x) compared to the Asian Personal Products industry average (20.9x).

PE vs Market: GSKCH is poor value based on its PE Ratio (12.8x) compared to the PK market (5.7x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GSKCH's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: GSKCH is overvalued based on its PB Ratio (4.1x) compared to the XA Personal Products industry average (1.8x).

Future Growth

How is GlaxoSmithKline Consumer Healthcare Pakistan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

14.0%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKline Consumer Healthcare Pakistan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has GlaxoSmithKline Consumer Healthcare Pakistan performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

19.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GSKCH has a high level of non-cash earnings.

Growing Profit Margin: GSKCH's current net profit margins (8.8%) are higher than last year (6.4%).

Past Earnings Growth Analysis

Earnings Trend: GSKCH's earnings have grown by 19.5% per year over the past 5 years.

Accelerating Growth: GSKCH's earnings growth over the past year (69.1%) exceeds its 5-year average (19.5% per year).

Earnings vs Industry: GSKCH earnings growth over the past year (69.1%) exceeded the Personal Products industry 11%.

Return on Equity

High ROE: GSKCH's Return on Equity (31.8%) is considered high.

Financial Health

How is GlaxoSmithKline Consumer Healthcare Pakistan's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: GSKCH's short term assets (PKR10.0B) exceed its short term liabilities (PKR6.9B).

Long Term Liabilities: GSKCH's short term assets (PKR10.0B) exceed its long term liabilities (PKR294.3M).

Debt to Equity History and Analysis

Debt Level: GSKCH has more cash than its total debt.

Reducing Debt: Insufficient data to determine if GSKCH's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: GSKCH's debt is well covered by operating cash flow (1386.1%).

Interest Coverage: GSKCH earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is GlaxoSmithKline Consumer Healthcare Pakistan current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GSKCH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GSKCH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GSKCH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GSKCH's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: GSKCH is not paying a notable dividend for the PK market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GSKCH has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Household industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure

CEO

Farhan Haroon

1.08yrs

Tenure

Mr. Farhan Muhammad Haroon serves as Chief Executive Officer and Executive Director at GlaxoSmithKline Consumer Healthcare Pakistan Limited since April 1, 2021. Mr. Haroon served as Chief Financial Officer...

Leadership Team

Experienced Management: GSKCH's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Experienced Board: GSKCH's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/16 00:00
End of Day Share Price	2022/05/16 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31